Beware of the "Normal" Troponin: A Critical Care Perspective

Dr Neeraj Manikath , claude.ai

Abstract

Cardiac troponins have revolutionized the diagnosis of myocardial injury, yet their interpretation remains fraught with clinical pitfalls. A "normal" troponin does not always exclude acute coronary syndrome (ACS), and clinicians must understand the temporal dynamics of troponin release, the limitations of assay sensitivity, and clinical scenarios where troponin levels may be falsely reassuring. This review addresses critical questions facing intensivists and emergency physicians: when should troponin testing be repeated, and in which conditions might troponin levels be misleadingly low? Understanding these nuances is essential for preventing diagnostic errors that can prove fatal.

Keywords: Troponin, acute coronary syndrome, myocardial infarction, high-sensitivity troponin, diagnostic timing

Introduction

Cardiac troponins (cTnI and cTnT) are the cornerstone biomarkers for diagnosing acute myocardial infarction (AMI). Their exquisite cardiac specificity and sensitivity have made them indispensable in modern cardiology and critical care practice.1,2 However, the mantra "troponin rules out MI" represents dangerous oversimplification. A single normal troponin value can provide false reassurance, potentially leading to premature discharge of patients with evolving myocardial infarction or missed diagnoses in specific clinical contexts.

The transition from conventional troponin assays to high-sensitivity troponin (hs-cTn) assays has improved early detection but has also introduced new interpretive challenges.3 This review focuses on two critical clinical scenarios that every intensivist must master: determining optimal timing for repeat troponin testing and recognizing conditions where troponin may be falsely low or undetectable despite genuine myocardial ischemia.

The Biology of Troponin Release: Understanding the Timeline

Kinetics of Troponin Elevation

Following acute myocardial injury, troponin begins appearing in peripheral blood within 2-4 hours, peaks at 12-24 hours, and may remain elevated for 7-14 days.4,5 However, this timeline represents average behavior and exhibits significant individual variation based on:

Infarct size: Larger infarcts produce earlier and higher peaks
Reperfusion status: Successful reperfusion accelerates troponin washout, causing earlier and higher peaks6
Collateral circulation: May delay or blunt troponin rise
Assay sensitivity: High-sensitivity assays detect elevations earlier than conventional assays7

The "Troponin-Negative" Window

The most dangerous period is the first 2-4 hours after symptom onset, when troponin levels may remain within normal limits despite ongoing myocardial infarction. Studies demonstrate that approximately 10-15% of patients with AMI present within this "troponin-negative window."8,9 This represents the primary rationale for serial troponin testing.

Pearl #1: Never discharge a patient with suspected ACS based on a single troponin drawn within 3 hours of symptom onset, regardless of assay sensitivity.

When to Repeat Troponin Testing

Evidence-Based Protocols

Conventional Troponin Assays

With conventional assays, the standard approach requires:

Baseline troponin at presentation
Repeat testing at 6-12 hours after symptom onset10,11
Additional testing at 12-24 hours if clinical suspicion remains high

High-Sensitivity Troponin Assays

The advent of hs-cTn assays has enabled accelerated diagnostic protocols:12,13

0/1-Hour Protocol (ESC Guidelines):14

Baseline hs-cTn at presentation
Repeat at 1 hour
Rule-out criteria: Both values below assay-specific cutoffs AND absolute change <5 ng/L
Rule-in criteria: Baseline >5× URL OR absolute change ≥20% and baseline elevated

0/2-Hour Protocol (Alternative):15

Baseline and 2-hour testing
Provides slightly higher sensitivity for presentations very early after symptom onset
May be preferred when presentation time is uncertain

0/3-Hour Protocol (ACEP Guidelines):16

More conservative approach
Baseline and 3-hour testing
Reduces false-negative rate when symptom onset timing is unclear

Clinical Scenarios Requiring Extended Serial Testing

1. Delayed Presentation

Patients presenting >24 hours after symptom onset may have passed the peak troponin window. Consider:

Troponin at presentation and 6 hours later
Look for downward trend (suggesting peak has passed)
Correlate with ECG evolution and imaging findings17

2. Stutter Symptoms

Patients with stuttering chest pain over hours to days:

Each symptomatic episode may represent a separate ischemic event
Repeat troponin 3-6 hours after each significant symptomatic episode18
Rising or persistently elevated troponins suggest ongoing injury

3. High-Risk Features Despite Normal Initial Troponin

Dynamic ECG changes (even if non-diagnostic)
Hemodynamic instability
High-risk clinical features (GRACE score >140)19
History of proven coronary artery disease
Action: Repeat troponin at 3-6 hours AND consider provocative testing or imaging

4. Renal Dysfunction

Chronic kidney disease (CKD) creates interpretive challenges:

Chronically elevated baseline troponins are common in CKD20
Rising or falling pattern (delta change) becomes more important than absolute values
Consider repeat testing at 6 hours with attention to:
- Absolute change >20% suggests acute injury21
- Stable chronic elevation suggests chronic myocardial injury or strain

Pearl #2: In patients with CKD and chronically elevated troponin, obtain baseline values during stable periods to establish individual "normal" for comparison during acute presentations.

5. Clinical-Laboratory Discordance

When clinical picture strongly suggests ACS but initial troponin is normal:

Repeat at 3 and 6 hours minimum
Do not rely solely on biomarkers—integrate clinical assessment, ECG, and imaging22
Consider immediate invasive or non-invasive imaging if very high suspicion

Oyster #1: A patient with ongoing chest pain, dynamic ST-segment changes, and "normal" troponin likely has sampling during the troponin-negative window or severe stenosis with intermittent ischemia. Do NOT wait for troponin elevation to act—these patients need urgent angiography.

Conditions Where Troponin May Be Falsely Low

1. Very Early Presentation (The Classic Pitfall)

Mechanism: Insufficient time for troponin to leak from injured cardiomyocytes into circulation

Clinical Context:

Patients presenting within 2-4 hours of symptom onset23
More problematic with conventional assays than hs-cTn assays
Even hs-cTn may be negative in first 1-2 hours in 5-10% of AMI patients24

Management Strategy:

Mandatory serial testing
Consider copeptin (if available) to improve early rule-out25
Rely heavily on clinical assessment and ECG findings
Low threshold for provocative testing or coronary CT angiography

Hack #1: In the first 3 hours after symptom onset, the ECG is actually MORE sensitive than troponin. Trust dynamic ECG changes over a single troponin value.

2. Small Infarcts and Microinfarctions

Mechanism: Limited myocardial necrosis producing troponin quantities below detection threshold

Clinical Context:

Distal vessel occlusions or small branch occlusions
Spontaneously reperfused STEMI with limited infarct size26
Microembolization during ACS or procedures
Early reperfusion limiting infarct size

Diagnostic Clues:

Regional wall motion abnormalities on echocardiography disproportionate to troponin level
New Q waves or T-wave inversions on ECG
Perfusion defects on nuclear imaging or cardiac MRI showing late gadolinium enhancement27

Management Strategy:

Do not dismiss ACS based solely on "negative" troponin if imaging shows infarction
Cardiac MRI is gold standard for detecting small infarcts28
Treat according to clinical syndrome, not biomarker levels alone

Pearl #3: Cardiac MRI can detect myocardial infarction as small as 1 gram of myocardium, well below the threshold for troponin detection.

3. Severe Proximal Coronary Occlusion (The Paradox)

Mechanism: Complete occlusion preventing troponin washout into circulation; the "stone heart" phenomenon

Clinical Context:

Acute complete occlusion of left main or proximal LAD
Cardiogenic shock with severely reduced cardiac output
Sudden cardiac death with successful resuscitation29

Clinical Features:

Profound hemodynamic compromise
Extensive ST-segment elevation
Rapidly evolving cardiogenic shock
Troponin may be normal or only minimally elevated initially

Pathophysiology: This counterintuitive scenario occurs because:

Complete occlusion prevents antegrade flow that would wash troponin into circulation
Severely reduced cardiac output limits biomarker distribution
Microvascular obstruction prevents troponin release30

Management Strategy:

Emergency angiography should NOT wait for troponin elevation
Clinical presentation and ECG findings take precedence
After revascularization, expect dramatic troponin surge

Oyster #2: The sickest MI patients may have the lowest initial troponins. If a patient is in cardiogenic shock with STEMI, don't wait for troponin confirmation—get them to the cath lab immediately.

4. Takotsubo Cardiomyopathy (Stress Cardiomyopathy)

Mechanism: Myocardial stunning without significant necrosis

Clinical Context:

Presents identically to acute MI (chest pain, dyspnea, ECG changes)
Triggered by emotional or physical stress31
Predominantly affects postmenopausal women
Characteristic apical ballooning on ventriculography

Troponin Patterns:

Usually elevated, but elevation is modest relative to extent of wall motion abnormality32
Peak troponin typically lower than expected for degree of LV dysfunction
Troponin may be normal in up to 10% of cases despite significant stunning33

Diagnostic Features:

Dramatic wall motion abnormalities extending beyond single coronary distribution
ECG changes (ST elevation or deep T wave inversions)
Normal or non-obstructive coronary arteries on angiography
Disproportionately low troponin for extent of dysfunction

Management Strategy:

Requires angiography to exclude coronary occlusion
Supportive care; usually complete recovery
Mimics acute MI closely—cannot reliably distinguish before angiography

Hack #2: If BNP/NT-proBNP is dramatically elevated (>10,000 pg/mL) but troponin is only mildly elevated, think Takotsubo over STEMI.

5. Reperfusion Before Testing

Mechanism: Spontaneous reperfusion or successful pre-hospital treatment limiting infarct size

Clinical Context:

Patients with spontaneous lysis of thrombus
Pre-hospital thrombolysis or antiplatelet/anticoagulant therapy
Intermittent coronary vasospasm (Prinzmetal's angina)34

Clinical Features:

Resolution of chest pain before ED arrival
ECG normalization or significant improvement
Normal or minimally elevated troponin at presentation
May have regional wall motion abnormalities on echo despite normal troponin

Management Strategy:

High index of suspicion for "aborted MI"
Proceed to angiography based on clinical presentation
Serial troponins may show late rise as necrotic myocardium releases remaining troponin
Cardiac MRI may reveal small areas of infarction35

Pearl #4: Pain resolution and ECG normalization do NOT exclude MI. These findings may indicate successful reperfusion, but the patient still needs risk stratification and likely angiography.

6. Assay Interference (Rare but Important)

Mechanism: Technical factors producing falsely low measurements

Causes:

Heterophile antibodies: Human anti-mouse antibodies (HAMA) interfering with immunoassays36
Biotin interference: High-dose biotin supplementation interfering with troponin assays using biotin-streptavidin technology37
Hemolysis: Can falsely lower cTnI in some assays (though usually causes falsely elevated results)38
Fibrin clots: Incomplete clotting may lead to falsely low results

Clinical Clues:

Clinical picture strongly suggestive of MI with unexpectedly normal troponin
Known use of biotin supplements (increasingly common)
Recent exposure to mouse proteins (unlikely in most settings)
Visibly hemolyzed samples

Management Strategy:

Repeat testing with new sample if interference suspected
Test on different analyzer platform if available
Stop biotin supplementation 72 hours before testing if possible
Ensure proper sample collection and handling

Hack #3: Always ask about supplement use, particularly biotin. Patients taking high-dose biotin (often for hair/nail health) may have falsely low troponin results.

7. Extreme Hemodilution

Mechanism: Dilutional effect lowering troponin concentration below detection threshold

Clinical Context:

Massive volume resuscitation
Extracorporeal membrane oxygenation (ECMO) initiation39
Continuous renal replacement therapy (CRRT) initiation
Post-cardiac surgery with massive transfusion

Clinical Features:

Temporally related to massive fluid administration
Other biomarkers also diluted (BNP, lactate, hemoglobin all decrease)
Clinical signs of fluid overload

Management Strategy:

Consider dilutional effect when interpreting all biomarkers
Correlate with clinical context and timing of resuscitation
May need higher index of suspicion for MI during massive resuscitation
Use imaging modalities (echo, cardiac MRI) when troponin unreliable

8. Coronary Vasospasm Without Infarction

Mechanism: Transient ischemia without sufficient myocyte necrosis to release detectable troponin

Clinical Context:

Prinzmetal's (variant) angina
Cocaine-associated chest pain40
Vasospastic angina in young women
Drug-induced vasospasm (amphetamines, ergotamines)

Clinical Features:

Typical anginal symptoms, often at rest or early morning
Transient ST-segment elevation during pain
Normal coronaries or minimal CAD on angiography
Positive provocative testing (acetylcholine, ergonovine)41

Troponin Patterns:

Usually normal unless vasospasm causes infarction
Prolonged vasospasm can lead to infarction with troponin elevation
Serial troponins may remain normal despite recurrent symptoms

Management Strategy:

Diagnosis requires high clinical suspicion
Provocative testing in cath lab for definitive diagnosis
Calcium channel blockers and nitrates for treatment
Avoid beta-blockers (may worsen vasospasm)

Pearl #5: ST elevation that resolves spontaneously with sublingual nitroglycerin suggests vasospasm. These patients need coronary angiography with provocative testing, not just troponin surveillance.

9. Chronic Total Occlusion with Established Collaterals

Mechanism: Well-developed collateral circulation preventing ischemia despite total occlusion

Clinical Context:

Patients with long-standing CAD
Gradual vessel occlusion allowing collateral development
May present with stable angina or be asymptomatic42

Clinical Features:

Minimal or no symptoms despite angiographic total occlusion
ECG may show old Q waves but no acute changes
Normal troponin despite severe anatomic disease
Viable myocardium supplied by collaterals

Management Strategy:

These patients are NOT having acute MI despite severe CAD
CTO revascularization is elective decision based on symptoms and ischemia burden
Normal troponin correctly reflects absence of acute injury

10. Demand Ischemia Without Type 1 MI

Mechanism: Supply-demand mismatch without atherosclerotic plaque rupture

Clinical Context:

Type 2 MI: severe anemia, hypotension, tachyarrhythmias, hypertensive emergency43
Severe sepsis or septic shock
Hypoxemic respiratory failure
Hypertrophic cardiomyopathy with dynamic obstruction

Troponin Patterns:

May be normal or elevated depending on duration and severity
When elevated, typically modest rise compared to Type 1 MI
Rise and fall kinetics may be slower than Type 1 MI44

Diagnostic Considerations:

Normal troponin doesn't exclude demand ischemia (may not cause necrosis)
ECG changes may be present without troponin elevation
Treatment focuses on correcting underlying cause

Oyster #3: Septic patients with troponin elevation have worse outcomes, but this usually represents septic cardiomyopathy or demand ischemia, not acute coronary occlusion. Don't rush them to the cath lab—optimize their hemodynamics.

Practical Approach: Clinical Decision-Making Framework

Step 1: Assess Pre-Test Probability

Use validated risk scores:

HEART Score: Useful for ED risk stratification45
GRACE Score: For confirmed ACS prognostication46
TIMI Risk Score: Alternative validated tool47

Step 2: Determine Optimal Troponin Strategy

High Pre-Test Probability (HEART ≥4):

Serial troponins mandatory regardless of initial value
Low threshold for urgent angiography if ECG concerning
Do not delay management for troponin results if STEMI or equivalent

Moderate Pre-Test Probability (HEART 3):

Use accelerated protocol (0/1h or 0/3h depending on assay)
If rule-out criteria met, consider stress testing before discharge
If rule-in criteria met, proceed to early invasive strategy

Low Pre-Test Probability (HEART 0-2):

Single troponin may suffice if hs-cTn assay used and presentation >3h from symptom onset
Consider alternative diagnoses
Consider stress testing for definitive exclusion if any doubt

Step 3: Recognize Red Flags for Falsely Low Troponin

Clinical Red Flags:

Presentation within 3 hours of symptom onset
Dynamic ECG changes despite normal troponin
Cardiogenic shock with minimal troponin elevation
Clinical picture highly suggestive of ACS
Known biotin supplementation

Action Plan:

Do not rely on single troponin value
Employ imaging (echo, CT coronary angiography, cardiac MRI)
Consider urgent/emergent angiography based on clinical picture
Remember: ECG and clinical assessment trump biomarkers in the first 3 hours

Step 4: Integrate Multi-Modal Assessment

Never rely on troponin alone. Integrate:

Clinical presentation (quality of pain, associated symptoms, risk factors)
Serial ECGs (perform every 10-15 minutes if ongoing pain)
Echocardiography (regional wall motion abnormalities precede troponin rise)
Advanced imaging when indicated (coronary CTA, cardiac MRI, nuclear imaging)

Special Populations and Scenarios

The Critically Ill Patient

Challenges:

Multiple confounders (sepsis, shock, renal failure, vasopressors)
Difficulty distinguishing Type 1 from Type 2 MI48
Limited ability to communicate symptoms
Hemodynamic instability limiting imaging options

Approach:

Serial troponins every 6-12 hours during critical illness
Trend troponin levels (rising, falling, or stable plateau)
Integrate bedside echo findings
Rising troponin with new wall motion abnormalities suggests Type 1 MI
Consider angiography if Type 1 MI suspected despite elevated baseline troponins

Hack #4: In the ICU patient with chronically elevated troponin, a rising trend + new regional wall motion abnormality on echo = Type 1 MI until proven otherwise.

Post-Cardiac Surgery

Challenges:

Troponin universally elevated after cardiac surgery49
Distinguishing expected post-operative rise from perioperative MI
Variable kinetics based on surgical technique and ischemic time

Troponin Patterns:

Expected rise: Peak at 12-24 hours post-op, then steady decline
Perioperative MI: Persistent elevation or secondary rise after initial decline50
Thresholds: >10× URL at 48 hours suggests significant perioperative MI

Diagnostic Approach:

Baseline troponin pre-operatively if possible
Serial post-operative troponins (6h, 12h, 24h, 48h)
New Q waves or persistent ST-segment changes suggest MI
Echo showing new regional wall motion abnormality
Rising troponin after initial decline is concerning

Cardiac Arrest Survivors

Challenges:

Global ischemia during arrest elevates troponin
Distinguishing primary cardiac cause from arrest-induced elevation51
Post-arrest myocardial stunning confounds assessment

Troponin Patterns:

Elevated in >90% of cardiac arrest survivors regardless of etiology
Very high levels (>10× URL) suggest primary cardiac cause
Kinetics may be delayed due to low-flow state

Diagnostic Strategy:

Do not exclude coronary cause based on normal initial troponin
Urgent angiography for all STEMI-equivalent post-arrest ECGs
Consider early angiography for non-diagnostic ECGs with high suspicion52
Serial troponins less useful than ECG and emergent coronary angiography

Emerging Technologies and Future Directions

Point-of-Care High-Sensitivity Troponin

Rapid turnaround time enabling faster rule-in/rule-out53
Comparable performance to central laboratory assays
May facilitate emergency department workflow

Novel Biomarkers

Copeptin: Improves early rule-out when combined with troponin54
Heart-type fatty acid binding protein (H-FABP): Earlier release than troponin55
MicroRNAs: Experimental but promising for very early detection56

Artificial Intelligence Integration

Machine learning algorithms combining clinical, ECG, and biomarker data
May improve risk stratification beyond individual parameters57
Validation in diverse populations ongoing

Key Clinical Pearls Summary

Pearl #1: Never discharge based on single troponin within 3 hours of symptom onset

Pearl #2: Establish baseline troponin in CKD patients during stable periods for acute comparison

Pearl #3: Cardiac MRI detects infarcts too small for troponin detection

Pearl #4: Pain resolution and ECG normalization don't exclude MI—may indicate reperfusion

Pearl #5: ST elevation resolving with nitroglycerin suggests vasospasm—needs provocative testing

Key Oysters (Unexpected Findings)

Oyster #1: Dynamic ECG changes with normal troponin need urgent angiography, not troponin surveillance

Oyster #2: Sickest MI patients (cardiogenic shock) may have lowest initial troponins

Oyster #3: Septic patients with elevated troponin rarely need cath lab—optimize hemodynamics first

Clinical Hacks

Hack #1: In first 3 hours, ECG is MORE sensitive than troponin—trust dynamic ECG changes

Hack #2: BNP >>10,000 with mild troponin elevation suggests Takotsubo over STEMI

Hack #3: Always ask about biotin supplements—can falsely lower troponin

Hack #4: ICU patient with rising troponin + new wall motion abnormality = Type 1 MI until proven otherwise

Conclusions

The "normal" troponin represents a common clinical pitfall with potentially fatal consequences. Clinicians must understand the temporal dynamics of troponin release, recognize the limitations of early testing, and identify clinical scenarios where troponin may be falsely reassuring. Serial testing remains the cornerstone of excluding AMI, but timing must be individualized based on symptom onset, clinical features, and assay characteristics.

High-sensitivity troponin assays have improved early detection but have not eliminated the need for clinical judgment. The integration of clinical assessment, serial ECGs, biomarker kinetics, and cardiac imaging provides the most robust approach to diagnosing or excluding acute coronary syndromes. Ultimately, no single biomarker can replace careful clinical reasoning and a thorough understanding of troponin biology.

The cardinal rule: When clinical suspicion is high, do not let a "normal" troponin provide false reassurance. Trust the patient's presentation, trust dynamic ECG changes, and when in doubt, pursue definitive testing. The most dangerous troponin result is the one that stops you from thinking.

References

Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651.
Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48(1):1-11.
Sandoval Y, Apple FS. The global need to define normality: the 99th percentile value of cardiac troponin. Clin Chem. 2014;60(3):455-462.
Adams JE 3rd, Bodor GS, Dávila-Román VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation. 1993;88(1):101-106.
Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007;53(4):547-551.
Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol. 1991;67(16):1360-1367.
Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858-867.
Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol. 2011;58(13):1332-1339.
Haaf P, Drexler B, Reichlin T, et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation. 2012;126(1):31-40.
Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med. 1997;337(23):1648-1653.
Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335(18):1342-1349.
Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267-315.
Neumann JT, Twerenbold R, Ojeda F, et al. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med. 2019;380(26):2529-2540.
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367.
Mueller C, Giannitsis E, Christ M, et al. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016;68(1):76-87.
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes. Circulation. 2014;130(25):e344-e426.
Eggers KM, Jernberg T, Ljung L, et al. High-sensitivity cardiac troponin T for early diagnosis of acute myocardial infarction. J Intern Med. 2012;271(3):271-281.
Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation. 2000;102(11):1216-1220.
Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091.
Dubin RF, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol. 2013;14:229.
Twerenbold R, Jaffe A, Reichlin T, et al. High-sensitive troponin T measurements: what do we gain and what are the challenges? Eur Heart J. 2012;33(5):579-586.
Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. 2000;342(16):1163-1170.
Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868-877.
Body R, Mueller C, Giannitsis E, et al. The Use of Very Low Concentrations of High-sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Baseline Blood Test. Acad Emerg Med. 2016;23(9):1004-1013.
Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54(1):60-68.
Gibbons RJ, Valeti US, Araoz PA, et al. The quantification of infarct size. J Am Coll Cardiol. 2004;44(8):1533-1542.

Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012;33(18):2252-2257.
Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445-1453.
Mullins KE, Christenson RH. The prognostic value of cardiac troponins. Scand J Clin Lab Invest Suppl. 1999;230:130-135.
Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97(8):765-772.
Templin C, Ghadri JR, Diekmann J, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med. 2015;373(10):929-938.
Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010;55(4):333-341.
Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018;39(22):2032-2046.
Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011;124(16):1774-1782.
Abdel-Aty H, Zagrosek A, Schulz-Menger J, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation. 2004;109(20):2411-2416.
Bolstad N, Warren DJ, Nustad K. Heterophilic antibody interference in immunometric assays. Best Pract Res Clin Endocrinol Metab. 2013;27(5):647-661.
Piketty ML, Polak M, Flechtner I, et al. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med. 2017;55(6):780-788.
Lippi G, Salvagno GL, Montagnana M, et al. Influence of hemolysis on routine clinical chemistry testing. Clin Chem Lab Med. 2006;44(3):311-316.
Rupprecht L, Flörchinger B, Schopka S, et al. Cardiac surgery for patients in cardiogenic shock requiring extracorporeal membrane oxygenation--an analysis of 171 patients. Eur J Cardiothorac Surg. 2013;44(2):269-274.
Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group. Acad Emerg Med. 1994;1(4):330-339.
Ong P, Athanasiadis A, Hill S, et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. 2008;52(7):523-527.
Werner GS, Surber R, Ferrari M, et al. The functional reserve of collaterals supplying long-term chronic total coronary occlusions in patients without prior myocardial infarction. Eur Heart J. 2006;27(20):2406-2412.
Sandoval Y, Jaffe AS. Type 2 Myocardial Infarction: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(14):1846-1860.
Saaby L, Poulsen TS, Hosbond S, et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med. 2013;126(9):789-797.
Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J. 2008;16(6):191-196.
Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345-2353.
Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-842.
Lim W, Qushmaq I, Devereaux PJ, et al. Elevated cardiac troponin measurements in critically ill patients. Arch Intern Med. 2006;166(22):2446-2454.
Muehlschlegel JD, Perry TE, Liu KY, et al. Troponin is superior to electrocardiogram and creatinine kinase MB for predicting clinically significant myocardial injury after coronary artery bypass grafting. Eur Heart J. 2009;30(13):1574-1583.
Thielmann M, Massoudy P, Jaeger BR, et al. Emergency re-revascularization with percutaneous coronary intervention, reoperation, or conservative treatment in patients with acute perioperative graft failure following coronary artery bypass surgery. Eur J Cardiothorac Surg. 2006;30(1):117-125.
Mullner M, Oschatz E, Sterz F, et al. The influence of chest compressions and external defibrillation on the release of creatine kinase-MB and cardiac troponin T in patients resuscitated from out-of-hospital cardiac arrest. Resuscitation. 1998;38(2):99-105.
Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv. 2010;3(3):200-207.
Apple FS, Sandoval Y, Jaffe AS, et al. Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care. Clin Chem. 2017;63(1):73-81.
Mockel M, Searle J, Muller R, et al. Chief complaints in medical emergencies: do they relate to underlying disease and outcome? The Charite Emergency Medicine Study (CHARITEM). Eur J Emerg Med. 2013;20(2):103-108.
O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006;114(6):550-557.
D'Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31(22):2765-2773.
Shouval R, Hadanny A, Shlomo N, et al. Machine learning for prediction of 30-day mortality after ST elevation myocardial infarction: An Acute Coronary Syndrome Israeli Survey data mining study. Int J Cardiol. 2017;246:7-13.

Supplementary Case Vignettes for Teaching

Case 1: The Very Early Presentation

Presentation: A 58-year-old man with hypertension and hyperlipidemia presents with crushing substernal chest pain that began 90 minutes ago while shoveling snow. Pain radiates to left arm, associated with diaphoresis.

Initial Evaluation:

Troponin I: 0.02 ng/mL (normal <0.04 ng/mL)
ECG: Subtle ST depression in V4-V6
Vital signs: BP 160/95, HR 98

Junior Resident's Plan: "Troponin is normal, let's observe and recheck in 6 hours."

Critical Care Pearl: This is the classic "troponin-negative window." The patient presented only 90 minutes after symptom onset—far too early for troponin to reliably exclude MI. The subtle ECG changes are concerning.

Correct Management:

Immediate aspirin, ticagrelor, anticoagulation
Repeat troponin at 3 hours (4.5 hours from symptom onset)
Continuous monitoring with serial ECGs
Low threshold for urgent angiography if ECG evolves or pain persists

Outcome: Repeat troponin at 3 hours was 2.8 ng/mL. Emergent angiography revealed 95% proximal LAD stenosis with visible thrombus. Successful PCI performed.

Teaching Point: Time from symptom onset matters more than the troponin value in the first 3 hours. Trust the clinical picture and ECG changes.

Case 2: The Shock Patient with "Low" Troponin

Presentation: A 62-year-old woman brought in by EMS with sudden onset chest pain, now in cardiogenic shock.

Initial Evaluation:

Troponin T: 0.15 ng/mL (mildly elevated; normal <0.01 ng/mL)
ECG: Anterolateral ST elevation (3-4 mm in V2-V6)
Vital signs: BP 75/50, HR 115, requiring norepinephrine
Echo: Severe global hypokinesis, EF 20%

Medical Student Question: "The troponin is only slightly elevated. Are we sure this is a STEMI?"

Critical Care Teaching: This is the paradox of severe proximal occlusion. The patient is in cardiogenic shock with massive STEMI, yet troponin is barely elevated because:

Complete occlusion prevents troponin washout into circulation
Severely reduced cardiac output limits biomarker distribution
No time has elapsed for significant troponin release

Correct Management:

Activate cath lab IMMEDIATELY—do NOT wait for troponin to rise
Mechanical circulatory support (consider Impella or IABP)
Emergent PCI

Outcome: Left main occlusion found. After PCI and Impella support, troponin peaked at 187 ng/mL at 24 hours—but initial low level almost caused dangerous delay.

Teaching Point: The sickest MI patients may have the lowest initial troponins. STEMI diagnosis is clinical and electrocardiographic—troponin confirmation is not required for cath lab activation.

Case 3: The Biotin Interference

Presentation: A 45-year-old woman with chest pain, presented 8 hours after symptom onset.

Initial Evaluation:

Troponin I: Undetectable (<0.01 ng/mL)
ECG: T wave inversions in inferior leads
Echo: Hypokinesis of inferior wall

Cardiologist: "This doesn't make sense. Echo shows acute injury but troponin is undetectable 8 hours out. Let's repeat on a different analyzer."

Second troponin (different platform): 8.5 ng/mL—clearly elevated

Investigation: Patient was taking 10,000 mcg/day of biotin for hair and nail health. First assay used biotin-streptavidin technology, which was subject to biotin interference causing falsely low results.

Critical Care Pearl: Always ask about supplements. High-dose biotin supplementation is increasingly common and can cause falsely low troponin results on certain assay platforms.

Teaching Point: Assay interference is rare but important. When clinical picture and biomarkers don't align, consider technical factors and repeat testing.

Case 4: The CKD Patient with Chronic Elevation

Presentation: A 70-year-old man with ESRD on hemodialysis presents with chest pain.

Initial Evaluation:

Troponin T: 0.18 ng/mL (his baseline is typically 0.15-0.20 ng/mL)
ECG: Non-specific changes, unchanged from prior
No dialysis for 3 days (missed sessions)

Emergency Physician: "His troponin is elevated, so we're admitting for NSTEMI."

Nephrologist: "Wait—check his baseline. He's always elevated due to CKD."

Critical Management Decision:

Obtained troponin from 2 months ago during routine labs: 0.16 ng/mL
Current level (0.18 ng/mL) represents only 12.5% change—within normal variation
Serial troponins at 0, 3, and 6 hours: 0.18, 0.19, 0.17 ng/mL (stable)
ECG unchanged, echo unchanged from prior
Diagnosis: Non-cardiac chest pain in CKD patient with chronically elevated troponin

Teaching Point: In CKD patients:

Establish baseline troponin during stable periods
Look for CHANGE (>20% rise or fall) rather than absolute values
Serial testing showing stability argues against acute MI
Integrate clinical picture—don't diagnose MI on troponin alone in CKD

Case 5: The Takotsubo Mimic

Presentation: A 68-year-old woman presents with chest pain one hour after learning of her husband's sudden death.

Initial Evaluation:

Troponin I: 0.85 ng/mL (mildly elevated)
ECG: Anterior ST elevation
Echo: Severe apical and mid-ventricular akinesis, EF 30%
BNP: 14,500 pg/mL

STEMI Alert Called: Patient taken emergently to cath lab

Angiogram: Normal coronary arteries—no stenosis, no thrombus

Ventriculogram: Classic apical ballooning ("octopus pot" appearance)

Critical Observation: The resident notes, "The troponin seems low for that degree of LV dysfunction—the entire apex isn't moving!"

Diagnosis: Takotsubo (stress) cardiomyopathy

Teaching Points:

Troponin in Takotsubo is typically elevated but modest relative to degree of dysfunction
Very high BNP with relatively low troponin is a clue
Emotional stressor in postmenopausal woman is classic
Angiography required to confirm diagnosis (can't distinguish from MI clinically)
Management is supportive; usually complete recovery

Summary Algorithm: When to Worry About "Normal" Troponin

Patient with suspected ACS and normal troponin
                    ↓
    ┌───────────────┴───────────────┐
    ↓                               ↓
Presentation <3 hours          Presentation ≥3 hours
from symptom onset             from symptom onset
    ↓                               ↓
HIGH RISK                      Check clinical features
• Mandatory serial testing     • ECG changes?
• Do not exclude MI           • High-risk features?
• ECG findings trump troponin  • HEART score ≥4?
• Low threshold for cath lab   ↓
                              ┌─┴─┐
                              ↓   ↓
                            YES  NO
                              ↓   ↓
                         Serial testing  Consider single
                         required       troponin sufficient
                                       (if hs-cTn used)

Red Flags Requiring Serial Testing Regardless:

Dynamic ECG changes
Ongoing chest pain
Hemodynamic instability
Known CAD with typical symptoms
Diabetes with anginal equivalent
GRACE score >140

Final Thought: A Philosophy of Troponin Interpretation

Troponin is an extraordinarily powerful biomarker, but it is not infallible. The best clinicians understand that troponin must be interpreted within the context of:

Time: When was blood drawn relative to symptom onset?
Trend: Is this a single value or part of a serial pattern?
Clinical context: Does the troponin result fit the clinical picture?
ECG findings: Do electrical changes support or contradict the biomarker?
Imaging: What does direct visualization of the myocardium show?

The "normal" troponin can be the most dangerous laboratory result if it creates false reassurance. Conversely, an elevated troponin without clinical correlation can trigger unnecessary interventions. The art of medicine lies in synthesizing all available data into a coherent clinical picture.

Remember: You are treating the patient, not the laboratory value. When in doubt, serial testing, imaging, and direct visualization (angiography) provide definitive answers. The patient with ongoing chest pain and dynamic ECG changes deserves aggressive evaluation regardless of initial troponin values.

As Sir William Osler famously stated, "Listen to your patient; he is telling you the diagnosis." In the era of high-sensitivity troponins, we might add: "But don't let a single laboratory value override what your patient—and their ECG—are telling you."

Wednesday, October 1, 2025